MCM8作为脂肪肝的诊疗靶点及其应用
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- WOMEN & CHILDRENS MEDICAL CENTER AFFILIATED WITH GUANGZHOU MEDICAL UNIVERSITY
- Filing Date
- 2021-08-20
- Publication Date
- 2026-07-17
AI Technical Summary
In the current technology, the etiology of Kawasaki disease is unclear, traditional treatments have significant side effects, and 10% to 20% of children do not respond to traditional treatments. Other vasculitis diseases are difficult to cure, and there is a lack of effective multi-target treatment methods.
By detecting and regulating the expression of substances in MCM8 and its related pathways, and using MCM8 gene knockout mouse models and drug intervention, the cGAS-STING-I interferon signaling pathway can be regulated to diagnose and treat diseases caused by abnormal mitophagy function and abnormal activation of the cGAS-STING-I interferon signaling pathway.
It provides new diagnostic and treatment methods, reduces drug resistance to diseases, reduces the side effects of traditional drugs, and improves treatment efficacy, especially for vasculitis such as Kawasaki disease and systemic lupus erythematosus.
Smart Images
Figure HDA0004283361160000011 
Figure HDA0004283361160000012 
Figure HDA0004283361160000021